rofecoxib has been researched along with Gastrointestinal Hemorrhage in 35 studies
Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 9.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "To evaluate the potential clinical and economic consequences of rofecoxib prescription in Ontario, Canada, for patients with osteoarthritis (OA) aged >65 years who did not respond to paracetamol (acetaminophen) therapy." | 7.71 | Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. ( Attard, CL; Kong, SX; Marentette, MA; Marshall, JK; Pellissier, JM, 2001) |
| "In healthy subjects, treatment with rofecoxib, at 2 to 4 times the doses that are currently recommended for the treatment of patients with osteoarthritis, produced significantly less fecal blood loss than a therapeutic dose of ibuprofen and was equivalent to placebo." | 5.09 | A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. ( Bolognese, JA; Bowen, B; Cagliola, A; Hunt, RH; James, C; Mortensen, ER; Quan, H; Simon, TJ, 2000) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 5.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "To update the results of a previously performed analysis of the incidence of upper GI perforations, symptomatic gastroduodenal ulcers, and upper GI bleeding (PUBs) with rofecoxib compared with non-selective NSAIDs." | 4.82 | The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. ( Bolognese, JA; Reicin, AS; Simon, TJ; Watson, DJ; Yu, Q, 2004) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| "It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis." | 3.76 | Unbalanced reporting of benefits and harms in abstracts on rofecoxib. ( Gøtzsche, PC; Jørgensen, AW; Jørgensen, KJ, 2010) |
| "To investigate trends in mortality rates due to both myocardial infarction and gastrointestinal haemorrhage before and after rofecoxib withdrawal and the release of regulatory guidance regarding the use of other COX-2 inhibitors." | 3.76 | International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. ( Gunnell, D; Martin, RM; Metcalfe, C; Wheeler, BW, 2010) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| "To evaluate the potential clinical and economic consequences of rofecoxib prescription in Ontario, Canada, for patients with osteoarthritis (OA) aged >65 years who did not respond to paracetamol (acetaminophen) therapy." | 3.71 | Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. ( Attard, CL; Kong, SX; Marentette, MA; Marshall, JK; Pellissier, JM, 2001) |
| " Our patient had arthritis of the hips and chronic atrial fibrillation and was on warfarin therapy for stroke prevention; less than a week after starting celecoxib therapy, gastrointestinal bleeding and hypoprothrombinemia occurred." | 3.70 | Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. ( Davis, JV; Linder, JD; Mönkemüller, KE; Wilcox, CM, 2000) |
| "Rofecoxib is a selective cyclooxygenase-2 inhibitor that has been approved for the treatment of osteoarthritis and management of acute pain." | 1.33 | Ischemic colitis associated with rofecoxib. ( Feltri, M; Meucci, G; Minoli, G; Radaelli, F; Spinzi, G; Terruzzi, V, 2005) |
| " Dyspepsia and nausea were the most frequently reported adverse events." | 1.32 | Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. ( Layton, D; Riley, J; Shakir, SA; Wilton, LV, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 31 (88.57) | 29.6817 |
| 2010's | 2 (5.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jaksch, W | 1 |
| Dejaco, C | 1 |
| Schirmer, M | 1 |
| Jørgensen, AW | 1 |
| Jørgensen, KJ | 1 |
| Gøtzsche, PC | 1 |
| Metcalfe, C | 1 |
| Wheeler, BW | 1 |
| Gunnell, D | 1 |
| Martin, RM | 1 |
| Mamdani, M | 1 |
| Rochon, PA | 1 |
| Juurlink, DN | 1 |
| Kopp, A | 1 |
| Anderson, GM | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Gornet, JM | 1 |
| Hassani, Z | 1 |
| Modiglian, R | 1 |
| Lémann, M | 1 |
| Layton, D | 1 |
| Riley, J | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| James, MW | 1 |
| Hawkey, CJ | 2 |
| MacDonald, TM | 1 |
| Morant, SV | 1 |
| Goldstein, JL | 1 |
| Burke, TA | 1 |
| Pettitt, D | 1 |
| Oviedo, JA | 1 |
| Wolfe, MM | 1 |
| Takeuchi, K | 2 |
| Tanaka, A | 2 |
| Hayashi, Y | 1 |
| Kubo, Y | 1 |
| Lamarque, D | 1 |
| Watson, DJ | 2 |
| Yu, Q | 1 |
| Bolognese, JA | 3 |
| Reicin, AS | 1 |
| Simon, TJ | 3 |
| Bannwarth, B | 1 |
| Logeart, I | 1 |
| Vergult, G | 1 |
| Psaty, BM | 1 |
| Furberg, CD | 1 |
| Drazen, JM | 1 |
| Moride, Y | 1 |
| Ducruet, T | 1 |
| Boivin, JF | 1 |
| Moore, N | 1 |
| Perreault, S | 1 |
| Zhao, S | 1 |
| Radaelli, F | 1 |
| Feltri, M | 1 |
| Meucci, G | 1 |
| Spinzi, G | 1 |
| Terruzzi, V | 1 |
| Minoli, G | 1 |
| McCarthy, DM | 1 |
| Rahme, E | 1 |
| Nedjar, H | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 2 |
| Hunt, RH | 1 |
| Bowen, B | 1 |
| Mortensen, ER | 1 |
| James, C | 1 |
| Cagliola, A | 1 |
| Linder, JD | 1 |
| Mönkemüller, KE | 1 |
| Davis, JV | 1 |
| Wilcox, CM | 1 |
| Bombardier, C | 1 |
| Laine, L | 1 |
| Reicin, A | 1 |
| Shapiro, D | 1 |
| Burgos-Vargas, R | 1 |
| Davis, B | 1 |
| Day, R | 1 |
| Ferraz, MB | 1 |
| Hochberg, MC | 1 |
| Kvien, TK | 1 |
| Schnitzer, TJ | 1 |
| Delgado Fernández, M | 1 |
| Zambrana García, JL | 1 |
| Diez García, F | 1 |
| Caroli, A | 1 |
| Monica, F | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| García Rodríguez, LA | 1 |
| Wardle, EN | 1 |
| Marshall, JK | 1 |
| Pellissier, JM | 1 |
| Attard, CL | 1 |
| Kong, SX | 1 |
| Marentette, MA | 1 |
| Brinker, AD | 1 |
| Bonnel, RA | 1 |
| Feight, AG | 1 |
| Nourjah, P | 1 |
| de La Serna Higuera, C | 1 |
| Rodríguez-Gómez, SJ | 1 |
| Martín Arribas, MI | 1 |
| Martínez Moreno, J | 1 |
| Foral, PA | 1 |
| Wilson, AF | 1 |
| Nystrom, KK | 1 |
| Freitas, J | 1 |
| Farricha, V | 1 |
| Nascimento, I | 1 |
| Borralho, P | 1 |
| Paramés, A | 1 |
| Araki, H | 1 |
| Hase, S | 1 |
| Komoike, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819] | Phase 2 | 150 participants | Interventional | 2001-11-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for rofecoxib and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
4 years after withdrawal of rofecoxib: where do we stand today?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Contraindications; Cyclooxygenase | 2008 |
Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2003 |
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Di | 2003 |
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Ul | 2004 |
Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cyclooxygenase Inhibitors; Diclofenac; Gas | 2002 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
2 trials available for rofecoxib and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chromium Radioisotopes; Cyclooxygenase 2; Cyclooxyge | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
26 other studies available for rofecoxib and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Unbalanced reporting of benefits and harms in abstracts on rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Gastrointest | 2010 |
International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction.
Topics: Acute Disease; Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Female; Gastrointestinal Hemorr | 2010 |
Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2; Diclofen | 2002 |
Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib.
Topics: Adult; Colonic Diseases; Crohn Disease; Cyclooxygenase Inhibitors; Female; Gastrointestinal Hemorrha | 2002 |
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inh | 2003 |
[Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclo | 2003 |
Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bias; Celecoxib; Cohort Studies; Databases, Factual; Family | 2003 |
Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility.
Topics: Animals; Atropine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinopro | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
[Prescribing patterns of rofecoxib in the primary care setting: results of a French survey].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Arthritis; Arth | 2004 |
COX-2 inhibitors--lessons in drug safety.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2005 |
COX-2 inhibitors--a lesson in unexpected problems.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ca | 2005 |
Ischemic colitis associated with rofecoxib.
Topics: Abdominal Pain; Colitis, Ischemic; Colon; Cyclooxygenase Inhibitors; Female; Gastrointestinal Hemorr | 2005 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 I | 2007 |
Rofecoxib for osteoarthritis and pain.
Topics: Analgesics; Cyclooxygenase Inhibitors; Diarrhea; Drug Interactions; Dyspepsia; Edema; Enzyme Inhibit | 1999 |
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis; Atrial Fibrillation; Bicar | 2000 |
Upper gastrointestinal toxicity of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Ethics, Medical; Gastrointestinal Hemorr | 2001 |
Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis.
Topics: Aged; Cyclooxygenase Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Lactones; Osteoarthrit | 2001 |
Cyclo-oxygenase-2 inhibitors to treat gastrointestinal bleeding.
Topics: Cyclooxygenase Inhibitors; Gastrointestinal Hemorrhage; Humans; Hypertension; Kidney; Lactones; Sulf | 2001 |
Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygena | 2001 |
Celecoxib and rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemo | 2001 |
[Rofecoxib-induced upper gastrointestinal bleeding].
Topics: Cyclooxygenase Inhibitors; Gastrointestinal Hemorrhage; Humans; Lactones; Sulfones | 2002 |
Gastrointestinal bleeds associated with rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Gastrointestinal Hemorrhag | 2002 |
Rofecoxib: a possible cause of acute colitis.
Topics: Acute Disease; Colitis; Cyclooxygenase Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Lact | 2002 |
Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury.
Topics: Amino Acid Sequence; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygen | 2002 |